Trials / Completed
CompletedNCT04537910
A Study of LY3819253 (LY-CoV555) in Healthy Participants
A Randomized, Placebo-Controlled, Participant- and Investigator-Blind, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of LY3819253 Administered Subcutaneously to Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection just under the skin to healthy participants. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it. Participation could last up to 16 weeks and may include up to six visits to the study center, with a one-week overnight stay.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3819253 | Administered SC. |
| DRUG | Placebo | Administered SC. |
Timeline
- Start date
- 2020-09-02
- Primary completion
- 2020-12-28
- Completion
- 2020-12-28
- First posted
- 2020-09-03
- Last updated
- 2021-12-06
- Results posted
- 2021-12-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04537910. Inclusion in this directory is not an endorsement.